Brought to you by 
Lonza acquires UCB-Bioproducts, UCB's manufacturing arm
07 Mar 2006
Executive Summary
Swiss specialty chemicals company Lonza has acquired UCB-Bioproducts, the peptide-drug-manufacturing business of Belgian pharmaceutical company UCB. The deal builds on a long-term supply agreement established last May between the two, under which Lonza is manufacturing PEGylated antibody-fragment-based bulk actives for UCB.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lonza acquires UCB-Bioproducts, UCB's manufacturing arm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice